Skip to Content

Clinical Trial Details

A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxel in Combination with Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects with Er, PgR, and Her2 Negative (Triple Negative) Metastatic Breast Cancer - “tnAcity”

IRB Protocol Number
ACCRU RU011303s Celgene ABI-007-MBC-001

Clinical Trial Categories

  • Breast Cancer
Barbara Beauchemin, RN, BSN at 603-224-2556


  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: 603-230-6000